Connect with us

Science

Every Vaccine and Treatment in Development for COVID-19, So Far

Published

on

Every Vaccine and Treatment in Development for COVID-19, So Far

covid-19 innovations pipeline-prev

Every Vaccine and Treatment in Development for COVID-19

As the number of confirmed COVID-19 cases continues to skyrocket, healthcare researchers around the world are working tirelessly to discover new life-saving medical innovations.

The projects these companies are working on can be organized into three distinct groups:

  1. Diagnostics: Quickly and effectively detecting the disease in the first place
  2. Treatments: Alleviating symptoms so people who have disease experience milder symptoms, and lowering the overall mortality rate
  3. Vaccines: Preventing transmission by making the population immune to COVID-19

Today’s graphics provide an in-depth look at who’s in the innovation race to defeat the virus, and they come to us courtesy of Artis Ventures, a venture capital firm focused on life sciences and tech investments.

Editor’s note: R&D is moving fast on COVID-19, and the situation is quite fluid. While today’s post is believed to be an accurate snapshot of all innovations and developments listed by WHO and FDA as of March 30, 2020, it is possible that more data will become available.

Knowledge is Power

Testing rates during this pandemic have been a point of contention. Without widespread testing, it has been tough to accurately track the spread of the virus, as well as pin down important metrics such as infectiousness and mortality rates. Inexpensive test kits that offer quick results will be key to curbing the outbreak.

Here are the companies and institutions developing new tests for COVID-19:

covid-19 diagnostics in development

The ultimate aim of companies like Abbott and BioFire Defense is to create a test that can produce accurate results in as little as a few minutes.

In the Trenches With Coronavirus

While the majority of people infected with COVID-19 only experience minor symptoms, the disease can cause severe issues in some cases – even resulting in death. Most of the forms of treatment being pursued fall into one of two categories:

  1. Treating respiratory symptoms – especially the inflammation that occurs in severe cases
  2. Antiviral growth – essentially stopping viruses from multiplying inside the human body

Here are the companies and institutions developing new treatment options for COVID-19:

covid-19 treatment in development

A wide range of players are in the race to develop treatments related to COVID-19. Pharma and healthcare companies are in the mix, as well as universities and institutes.

One surprising name on the list is Fujifilm. The Japanese company’s stock recently shot up on the news that Avigan, a decades-old flu drug developed through Fujifilm’s healthcare subsidiary, might be effective at helping coronavirus patients recover. The Japanese government’s stockpile of the drug is reportedly enough to treat two million people.

Vaccine

The progress that is perhaps being watched the closest by the general public is the development of a COVID-19 vaccine.

Creating a safe vaccine for a new illness is no easy feat. Thankfully, rapid progress is being made for a variety of reasons, including China’s efforts to sequence the genetic material of Sars-CoV-2 and to share that information with research groups around the world.

Another factor contributing to the unprecedented speed of development is the fact that coronaviruses were already on the radar of health science researchers. Both SARS and MERS were caused by coronaviruses, and even though vaccines were shelved once those outbreaks were contained, learnings can still be applied to defeating COVID-19.

covid-19 vaccines in development

One of the most promising leads on a COVID-19 vaccine is mRNA-1273. This vaccine, developed by Moderna Therapeutics, is being developed with extreme urgency, skipping straight into human trials before it was even tested in animals. If all goes well with the trials currently underway in Washington State, the company hopes to have an early version of the vaccine ready by fall 2020. The earliest versions of the vaccine would be made available to at-risk groups such as healthcare workers.

Further down the pipeline are 15 types of subunit vaccines. This method of vaccination uses a fragment of a pathogen, typically a surface protein, to trigger an immune response, teaching the body’s immune system how to fight off the disease without actually introducing live pathogens.

No Clear Finish Line

Unfortunately, there is no silver bullet for solving this pandemic.

A likely scenario is that teams of researchers around the world will come up with solutions that will incrementally help stop the spread of the virus, mitigate symptoms for those infected, and help lower the overall death toll. As well, early solutions rushed to market will need to be refined over the coming months.

We can only hope that the hard lessons learned from fighting COVID-19 will help stop a future outbreak in its tracks before it becomes a pandemic. For now, those of us on the sideline can only do our best to flatten the curve.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Comments

Misc

Visualizing the Power and Frequency of Earthquakes

Our planet is in a constant state of creation and destruction as the plates of the earth collide. This visualization looks at earthquake magnitude.

Published

on

Earthquake Magnitude

Visualizing the Power and Frequency of Earthquakes

The surface of our planet is in a constant state of creation and destruction as the plates of the Earth collide. It is this movement of the Earth’s crust that causes earthquakes, sending tremors throughout the world.

Today’s graphic is inspired by a classic USGS diagram that tracks the scale and frequency of earthquakes.

Shifting Foundations

Earthquakes occur because the crust of the Earth is made up of several plates. The boundaries of these plates create faults that can run into one another.

Earthquakes describe both the mechanism that causes a sudden stress release along plate boundaries and also the ensuing ground shaking.

They occur when stress builds up along a tectonic fault. This stress causes the two surfaces of the fault, which had previously been stuck together due to friction, to suddenly move, or slide, releasing energy in the form of seismic waves.

Measuring an Earthquake’s Impact

There are three factors to assess the impact of Earthquakes – magnitude, energy, and intensity.

Magnitude is a number most commonly associated with the Richter scale, describing the size of an Earthquake on a scale from 0 to 10 – the latter of which is the maximum motion recorded by a seismograph. Each increase by one on the scale represents a tenfold increase in the amplitude. There are over a million tremors around the planet each year, but it’s not until an earthquake reaches a magnitude of 4 that humans can typically feel it.

Another way to measure the size of an earthquake is by how much energy it releases. The amount of energy radiated by an earthquake is a measure of the potential for damage to man-made structures.

An earthquake releases energy at various frequencies, and in order to calculate accurately, you have to include all frequencies of shaking for the entire event. Some research suggests technology could harness this energy for power generation.

Intensity describes the severity of an earthquake with a qualitative evaluation of its effects on the Earth’s surface and on the built environment. An earthquake may have a high magnitude but if a city or landscape experiences little damage, it can be said that the intensity is low. The Modified Mercalli Intensity Scale measures this intensity.

The World’s Largest Earthquakes by Magnitude

Prior to the development and use of seismographs, around 1900, scientists could only estimate magnitudes, based on historical reports of the extent and severity of damage.

DateLocationMagnitude
May 22, 1960Valdivia, Chile9.4-9.6
March 27, 1964Prince William Sound, Alaska9.2
Dec. 26, 2004Indian Ocean, Sumatra, Indonesia9.1
March 11, 2011Pacific Ocean, Tohoku Region, Japan9.1
July 8, 1730Valparaiso, Chile9.1-9.3 (est.)
Nov. 4, 1952Kamchatka, Russia9
Aug. 13, 1868Arica, Chile8.5-9.0 (est.)
January 26, 1700Pacific Coast, Modern Day British Columbia8.7-9.2 (est.)
April 2, 1762Chittagong, Bangladesh8.8 (est.)
Nov. 25, 1833Sumatra Indonesia8.8 (est.)

Earthquakes are a fact of life on Earth and mark distinct moments in history. One would think given our knowledge of earthquakes, that humans would avoid these locations – however, the very faults of the Earth also create its greatest advantages.

Living with Your Faults

It’s extremely common to find human settlements along the fault lines where earthquakes occur most frequently. Some could say that this is because these decisions were made before a complete understanding of science enabled us to know the potential risks involved.

However, a recent scientific study reveals that there may be more to the pattern than previously thought. Tectonically active plates may have produced greater biodiversity, more food, and water for our human predecessors.

Certain landscape features formed by tectonic processes such as cliffs, river gorges, and sedimentary valleys create environments that support access to drinking water, shelter, and an abundant food supply.

This inherent problem reveals that humans are more connected to their environments than previously thought. It comes down to a question of how well humans can adapt their lifestyle and built environments to a dynamic planet.

Now let’s worry about the asteroids

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Science

Visualizing the Huge Potential of Minor Cannabinoids

While the broader cannabis market is estimated to reach $45B by 2024, we’ve only scratched the surface in harnessing the potential of minor cannabinoids.

Published

on

The Huge Potential of Minor Cannabinoids

Hemp and marijuana are increasingly recognized for their exciting investment potential.

Due to their growing list of health benefits, the dominant conversation tends to center around the most abundant cannabinoids—cannabidiol (CBD) and tetrahydrocannabinol (THC). As a result, the cannabinoid market is estimated to reach almost $45 billion by 2024.

But CBD and THC are just two cannabinoids out of over a hundred that have been discovered to date. Today’s graphic from Trait Biosciences explores the hidden potential of the lesser-known minor cannabinoids, and illustrates how they fare in comparison to their major counterparts.

Cannabinoids 101

Cannabinoids are chemical compounds found in both hemp and marijuana that mimic compounds found in the human endocannabinoid system. This system is made up of a network of receptors that are involved in physiological processes like mood and memory.

When cannabis is consumed, cannabinoids interact with these receptors and produce different effects depending on the receptors they bind to. Although over a hundred cannabinoids have been found, they are not all created equally. They are typically divided into two categories:

  • Major cannabinoids: More plentiful
  • Minor cannabinoids: Less plentiful

Regardless of whether a cannabinoid is categorized as major or minor, every cannabinoid starts out as a form of CBG.

CBG-A: The Mother of All Cannabinoids

Cannabigerolic acid, or as it is more commonly known, CBG-A, is the acid precursor to other cannabinoid acids such as THC-A, and CBD-A. When the acids are exposed to heat, or prolonged UV light, they convert to neutral cannabinoids such as CBD and THC.

While CBG is regarded as a minor cannabinoid, it boasts a wide range of benefits that are urging researchers and scientists to take notice:

  • Fights inflammation
  • Soothes pain
  • Reduces nausea
  • Slows the spread of cancer cells
  • Helps treat glaucoma

CBG could be hugely beneficial in treating a wide variety of diseases, but it’s just one of many minor cannabinoids that could potentially blow CBD and THC out of the water.

The Potential of Minor Cannabinoids

To date, there has been limited research into the power of minor cannabinoids. However, the results from preliminary research look incredibly promising.

CannabinoidTypeExamples of potential medical application
THC
Tetrahydrocannabinol
Major, psychoactive
Parkinson’s disease, epilepsy, autoimmune diseases
CBD
Cannabidiol
Major, non-psychoactive
Epilepsy, schizophrenia
CBG-A
Cannabigerolic acid
Minor, non-psychoactive
Metabolic disorders, colon cancer
THC-A
Tetrahydrocannabinolic acid
Minor, non-psychoactive
Arthritis, neurodegenerative diseases, nausea, appetite loss
CBD-A
Cannabidiolic acid
Minor, non-psychoactive
Chemotherapy-induced nausea/vomiting (CINV), depression
CBC-A
Cannabichromene acid
Minor, non-psychoactive
Fungal diseases
CBG
Cannabigerol
Minor, non-psychoactive
Crohn’s disease, bowel disease, certain cancers
CBD-V
Cannabidivarin
Minor, non-psychoactive
Seizure prevention, Rett syndrome, Duchenne muscular dystrophy (DMD)
CBC-V
Cannabichromevarin
Minor, non-psychoactive
Osteoporosis, ALS, Muscular dystrophy
CBC
Cannabichromene
Minor, non-psychoactive
Could inhibit growth of cancer cells, osteoarthritis, neurological diseases
THC-V
Tetrahydrocannabivarin
Minor, psychoactive
Diabetes, anxiety, PTSD
Alzheimer’s disease
CBN
Cannabinol
Minor, psychoactive
Bacterial infections, ALS ,appetite stimulant

Note: Any potential medical treatment listed here stems from preclinical/animal testing only, and is simply intended to illustrate the potential application of each cannabinoid rather than a proven benefit.

Scientists also recently discovered two new cannabinoids—THC-P and CBD-P—with research showing that THC-P could potentially be 30 times more potent than THC.

The Future of Minor Cannabinoids

FDA-approved CBD drug Epidiolex has sparked a rising interest in minor cannabinoid trials.

In fact, the National Institutes of Health (NIH) has committed to providing funding to strengthen the evidence for minor cannabinoids and their pain relieving properties.

Cannabinoids could also add great value to cancer treatment-related side effects, however, more research is needed to turn potential into proof. With the availability of more robust evidence, the potential medical applications for minor cannabinoids could be much greater than we can imagine.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Subscribe

Join the 190,000+ subscribers who receive our daily email

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Popular